TY  - JOUR
T1  - CAncer drug resistance
AU  - Hampton T
Y1  - 2013/01/02
N1  - 10.1001/jama.2012.173440
JO  - JAMA
SP  - 20
EP  - 20
VL  - 309
IS  - 1
N2  - 
The researchers identified MED12 when looking for genes that, when suppressed, confer resistance to the targeted therapy crizotinib in non–small cell lung cancer cells. They then found that MED12 inhibition resulted in resistance not only to crizotinib, but also to other targeted drugs and chemotherapy used to treat colon cancer, melanoma, and liver cancer. Previous research has revealed mutations in MED12 in various types of cancer cells.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2012.173440
UR  - http://dx.doi.org/10.1001/jama.2012.173440
ER  -